Eduardo

Eduardo, on behalf of Yi Chen, inquired about the target level of lesion growth inhibition for the Geographic Atrophy (GA) trial to be considered successful. He also asked about the capital allocation strategy for LBS-009, its prioritization, expected timing for a Phase I study, and any details on a specific liver indication.

Answer

Chairman and CEO Tom Lin stated there are no current plans for LBS-009, as the company is prioritizing the successful launch of Tinlarebant. CMO Hendrik Scholl explained that while injectable GA treatments showed 13-21% efficacy, Belite Bio is ambitious for 15-20% or more with their oral compound, believing that achieving similar thresholds would establish it as the standard of care.

Eduardo inquired about the target level of lesion growth inhibition for the geographic atrophy (GA) trial to be considered successful. He also asked about capital allocation for LBS-009, its potential move into a Phase 1 study, and any details on a specific primary liver indication.

Answer

Chairman and CEO Tom Lin stated there are no current plans for LBS-009, as the company is prioritizing Tinlarebant's launch. CMO Hendrik Scholl explained that while injectable GA treatments showed 13-21% efficacy, an oral compound like theirs, even at a similar threshold (15-20%), would be a success and likely become the standard of care, given the convenience advantage.